Prospective comparison of subcutaneous vs intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and

被引：0
作者：
Moreau, P.
Coiteux, V.
Hulin, C.
Facon, T.
van de Velde, H.
Acharya, M.
Harousseau, J. L.
机构：
[1] Univ Hosp Nantes, Dept Hematol, Nantes, France
[2] Johnson & Johnson Pharmaceut R&D, Beerse, Belgium
[3] Johnson & Johnson Pharmaceut R&D, Raritan, NJ USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：158 / 158
页数：1
相关论文
共 50 条
  • [41] The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients
    Jung, Joo Young
    Kim, Ho Young
    Han, Boram
    Choi, Dae Ro
    Zang, Dae Young
    Kim, Hyo Jung
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [42] BLOOD DISTRIBUTION OF SUBCUTANEOUS BORTEZOMIB AND ITS KINETICS IN MULTIPLE MYELOMA PATIENTS
    Osawa, Takashi
    Naito, Takafumi
    Mino, Yasuaki
    Kawakami, Junichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S89 - S89
  • [43] An evaluation of efficiency, safety, tolerability, patient satisfaction, and preference of subcutaneous (SQ) versus intravenous (IV) bortezomib (BTZ) administration in patients with multiple myeloma (MM).
    Barbee, Meagan Spencer
    Wilson, Nicole Maire
    Harvey, R. Donald
    McKibbin, Trevor
    Lonial, Sagar
    Kaufman, Jonathan L.
    Shah, Katherine Sanvidge
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] A PHARMACOKINETICS CLINICAL STUDY OF BORTEZOMIB SUBCUTANEOUS INJECTION VERSUS INTRAVENOUS INJECTION COMBINED WITH CHEMOTHERAPY IN CHINESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA-INTERIM RESULTS
    Fu, C.
    Wu, D.
    Zhu, X.
    Jin, S.
    Yan, L.
    Yan, S.
    Wang, P.
    Ge, Y.
    Chang, M.
    HAEMATOLOGICA, 2016, 101 : 794 - 794
  • [45] Phase Ib Study Investigating the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Administration of ABBV-383 in Patients With Relapsed/Refractory Multiple Myeloma
    Gatt, Moshe
    Magen, Hila
    McKay, John
    Karlin, Lionel
    Touzeau, Cyrille
    Vincent, Laure
    Kapoor, Prashant
    Leleu, Xavier
    Uchida, Toshiki
    Weisel, Katja
    Bueno, Orlando
    Rosenberg, Tanya
    Ahsan, Aarif
    Jin, Ziyi
    Polepally, Akshanth
    Talati, Chetasi
    Pothacamury, Rajvineeth
    Chhabra, Saurabh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S54 - S55
  • [46] Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novopatients with multiple myeloma
    刘辉
    ChinaMedicalAbstracts(InternalMedicine), 2013, 30 (04) : 229 - 230
  • [47] Tolerance and efficacy of bortezomib in patients with multiple myeloma of poor prognosis
    Leleu, Xavier
    HEMATOLOGIE, 2007, 13 (03): : 136 - 136
  • [48] EFFICACY, SAFETY AND TOLERANCE OF BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
    Ballina, B.
    Fuertes, M.
    Cerda, S.
    Martinez Robles, V
    Gonzalez, P.
    Rondon, F.
    Yacoubi, S.
    Rodriguez, J. A.
    Escalante, F.
    HAEMATOLOGICA, 2017, 102 : 94 - 95
  • [49] Contemporary intravenous administration of Bortezomib, Melphalan and Dexamethasone in previously treated myeloma patients
    Di Raimondo, F.
    Chiarenza, A.
    Del Fabbro, V.
    Schinocca, L.
    Fiumara, P.
    Palumbo, G. A.
    Conticello, C.
    Amato, G.
    Giustolisi, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 163 - 164
  • [50] Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
    Arnulf, Bertrand
    Pylypenko, Halyna
    Groslcki, Sebastian
    Karamanesht, Ievgenii
    Leleu, Xavier
    van de Velde, Helgi
    Feng, Huaibao
    Cakana, Andrew
    Deraedt, William
    Moreau, Philippe
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (12): : 1925 - 1928
12345